ArticleJournal of advanced research2026

Development of a selectively AURKB targeting peptide degradation drug with artificial intelligence-assisted design for the treatment of acute lymphoblastic leukemia.

Yun Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.